ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants

MacroGenics Appoints New Senior Vice President of Clinical Development ROCKVILLE , Md. , January 7 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment

ROCKVILLE , Md. , July 13, 2009 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the trea tment of individuals with suspected central nervous system infection due to West Nile

Paulo F. Costa Joins MacroGenics Board of Directors ROCKVILLE, MD., June 23, 2009 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis

Phase 3 PROTÉGÉ ENCORE Clinical Trial Initiated

MacroGenics Appoints New Vice President of Business Development ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric

Proceeds to be Used for Advancement of Cancer Stem Cells and Other Development Programs

Raven's Discovery Platform in Cancer Stem Cell Biology<br>Enhances MacroGenics' Oncology Capabilities and Complements Proprietary Antibody Technology Platforms

Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer Rockville, Maryland.   May 6, 2008.  MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the

Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments

Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics

MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody

JDRF Provides MacroGenics with $2 Million in Funding for "Prot&#233;g&#233;" Trial

MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors Rockville , Maryland.  October 16, 2006.   MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the

Pivotal Trial of CD3 Monoclonal Antibody to Begin in 2006

Newly Published Data Validate CD32B as Key Target in Non-Hodgkins Lymphoma

MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs Rockville , Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of

MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it

MacroGenics Announces Grand Opening of New cGMP Manufacturing Facility in Montgomery County, Maryland Biotech Corridor ROCKVILLE, MD.  October 19 th , 2005.  MacroGenics, Inc. today announced the grand opening of its recently completed cGMP manufacturing facility located in Rockville, Maryland.

Phase 2 Clinical Trial Set to Begin

MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio

MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. For Immediate Release Rockville, MD, October 19, 2004  ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement

MacroGenics Completes Series B Financing For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of

CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 For MacroGenics Michael Richman - Exec. VP & CFO (301) 354-0681   For Immediate Release April 26, 2004 HORSHAM, Pa. , and ROCKVILLE , Md.